Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05484401 · ClinicalTrials.gov registry record · Phase 3

Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars

A Phase 3 study of Tooth Diseases and Tooth, Impacted, sponsored by Reckitt Benckiser Healthcare (UK) Limited.

Completed
Registry status
Phase 3
Development phase
294
Enrollment target
1
Study location

NCT05484401 is a Phase 3 study of Tooth Diseases and Tooth, Impacted that has completed, run by Reckitt Benckiser Healthcare (UK) Limited. The registered enrollment target is 294 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05484401, a Phase 3 study of Tooth Diseases and Tooth, Impacted, has completed, sponsored by Reckitt Benckiser Healthcare (UK) Limited.

COMPLETED
Registry status
Phase 3
Development phase
294 participants
Enrollment target
1
Study location

Study Summary

This is a single centre, three-arm randomised, double-blind, double-dummy, parallel group, single-dose, active and placebo-controlled efficacy and pharmacokinetics/ pharmacodynamics study to evaluate the efficacy and safety of 2 x 200 mg Ibuprofen Liquid Capsules in subjects with post-operative dental pain.

Interventions

  • OTHER Placebo Tablets
  • DRUG Ibuprofen 200Mg Oral Cap
  • DRUG Ibuprofen 200Mg Oral Tablet
  • OTHER Placebo Liquid Capsule

Study Locations (1)

Utah

  • JBR Clinical Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 294 participants
Start Date 2022-08-09
Est. Completion 2023-06-15
Phase Phase 3

What the Registry Record Tells You About NCT05484401

The ClinicalTrials.gov registry entry for NCT05484401 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reckitt Benckiser Healthcare (UK) Limited, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Tooth Diseases appearing as the primary indexed condition, and to 4 interventions - of which Placebo Tablets is the first listed.

NCT05484401 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT05484401 about?

NCT05484401 is a clinical study titled "Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars". This is a single centre, three-arm randomised, double-blind, double-dummy, parallel group, single-dose, active and placebo-controlled efficacy and pharmacokinetics/ pharmacodynamics study to evaluate the efficacy and safety of 2 x 200 mg Ibuprofen Liquid Capsules in subjects with post-operative dent...

What is the current status of trial NCT05484401?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 294 participants. The study started on 2022-08-09. Estimated completion is 2023-06-15.

What conditions does trial NCT05484401 study?

This clinical trial studies the following conditions: Tooth Diseases, Tooth, Impacted, Stomatognathic Diseases.

What interventions are being tested in trial NCT05484401?

The interventions under investigation include: Placebo Tablets (OTHER), Ibuprofen 200Mg Oral Cap (DRUG), Ibuprofen 200Mg Oral Tablet (DRUG), Placebo Liquid Capsule (OTHER).

Who is sponsoring clinical trial NCT05484401?

This trial is sponsored by Reckitt Benckiser Healthcare (UK) Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05484401 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tooth Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.